New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 26, 2012
12:22 EDTXOM, LEAP, BCO, SWI, PCS, ALU, AKAM, AET, PHM, REGN, XLNX, EQIX, CTXS, CHK, JNJ, UPS, NIHDOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday, in spite of jobless claims that were higher than expected and disappointing results from Exxon Mobil (XOM). Stocks began the day quietly following the jobless claims data. The averages were mixed in the opening half hour but spurted higher following the March pending home sales report. The data was much better than expected and pushed the averages to their session highs. The averages have since remained in a narrow range but have drifted higher... ECONOMIC EVENTS: Domestically, 388,000 initial jobless claims were reported, versus expectations of 375,000. Continuing claims came in at 3.31M, versus expectations for 3.29M. The Chicago Fed National Activity Index had a reading of -0.29. Pending home sales for the month of March were up 4.1% from the prior month, versus expectations of an increase of 1.0%... COMPANY NEWS: Exxon Mobil and UPS (UPS) both reported revenues and earnings that missed expectations, sending shares of both tumbling. Exxon slid almost 2% following its report, while UPS fell over 3%... Johnson & Johnson (JNJ) increased its dividend by 7%... Reuters reported that the SEC opened an informal inquiry into Chesapeake Energy's (CHK) well participation program as the company came out separately and said it did not review or approve of specific transactions made by its CEO Aubrey McClendon under that program... Among companies reporting earnings, advancers included Citrix Systems (CTXS), Equinix (EQIX), Xilinx (XLNX), Regeneron (REGN) and Pulte (PHM); decliners included Aetna (AET), Akamai (AKAM), Alcatel-Lucent (ALU) and MetroPCS (PCS)... MAJOR MOVERS: Among the notable gainers were SolarWinds (SWI), up 19%, after guiding to FY12 adjusted earnings that were above consensus at the midpoint, and Brinks (BCO), up over 17%, following results that beat on both the top and bottom line. Noteworthy losers included Leap Wireless (LEAP), down 20%, following downgrades at Raymond James and Guggenheim after its weak Q1 results, and NII Holdings (NIHD), down more than 18%, after its revenues and earnings disappointed... INDICES: Near noon, the Dow was up 63.46, or 0.48%, to 13,154.18; the Nasdaq was up 6.61, or 0.22%, to 3,036.24; and the S&P 500 was up 2.62, or 0.19%, to 1,393.31.
News For XOM;UPS;JNJ;CHK;CTXS;EQIX;XLNX;REGN;PHM;AET;AKAM;ALU;PCS;SWI;BCO;LEAP;NIHD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
October 14, 2014
08:58 EDTJNJJ&J sees FY14 operating sales on constant currency basis up 5.5%-6.5%
Subscribe for More Information
08:55 EDTXLNXBarclays top ideas in U.S. Semiconductors on the pullback
Barclays' top U.S. Semiconductor ideas to buy on the pullback are Avago (AVGO), Cavium (CAVM), Spansion (CODE), NXP Semiconductors (NXPI) and Xilinx (XLNX).
07:50 EDTJNJJohnson & Johnson: Alios BioPharma transaction expected to close in Q4 of 2014
Subscribe for More Information
07:50 EDTJNJJohnson & Johnson reports Q3 Worldwide Consumer sales down 0.6% to $3.6B
Subscribe for More Information
07:49 EDTJNJJohnson & Johnson raises FY14 EPS to $5.92-$5.97 from $5.85-$5.92
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson reports Q3 domestic sales up 11.6% to $8.84B
Reports Q3 international sales down 0.3% to $9.63B. Worldwide, domestic and international operational sales growth, excluding the impact of this divestiture, was 8.4%; 14.8% and 3.1% respectively.
07:46 EDTJNJJohnson & Johnson reports Q3 adjusted EPS $1.50, consensus $1.44
Subscribe for More Information
October 13, 2014
15:24 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
14:24 EDTJNJJohnson & Johnson October volatility increases into Q3 and outlook
Subscribe for More Information
14:15 EDTJNJEarnings Preview: Johnson & Johnson looks to new drugs to boost Q3 sales
Subscribe for More Information
14:08 EDTJNJJohnson & Johnson technical notes before earnings
Subscribe for More Information
09:23 EDTAKAM, EQIXHP could buy lower valuation company, says Bernstein
Subscribe for More Information
08:40 EDTJNJAlios BioPharma reports positive results for AL-8176 in Phase 2 study
Alios BioPharma presented results from a randomized, double-blind, placebo-controlled Phase 2 challenge study of its oral anti-RSV nucleoside analog AL-8176 this past weekend at the IDWeek 2014 Conference in Philadelphia, PA. The study was conducted in healthy adult volunteers who were infected intranasally with respiratory syncytial virus, or RSV. AL-8176 achieved its primary and secondary endpoints of reduction in viral load and improvement in symptom scores as compared to placebo. AL-8176 was well tolerated with no discontinuations of study drug and no clinically significant laboratory abnormalities. In successfully infected subjects, a rapid and marked reduction in RSV viral load was observed following treatment in all three AL-8176 treated dose groups as compared to placebo. In contrast, successfully infected placebo subjects exhibited a logarithmic increase in RSV RNA with a peak viral load at Day 3.5 following start of dosing with placebo. The mean time to non-detectability of RSV RNA was 1.3-2.3 days for the AL-8176 treatment groups compared to 7.2 days in the placebo group. At discharge, all subjects treated with AL-8176 were RSV RNA undetectable and remained RSV RNA undetectable upon follow-up on Days 16 and 28. The viral load reduction in infected subjects across all AL-8176 dosing regimens was associated with concomitant improvements in RSV symptom scores and reductions in mucus weight. On September 30, Johnson & Johnson announced a definitive agreement to acquire Alios.
08:05 EDTJNJBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:25 EDTJNJEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
07:15 EDTXOM, JNJ, AKAMNational Association of Corporate Directors to hold a conference
Subscribe for More Information
07:13 EDTJNJBioFlorida to hold a conference
Subscribe for More Information
06:36 EDTXOMSaudi Arabia content to let oil prices stay low, Reuters reports
Subscribe for More Information
October 12, 2014
13:53 EDTXOMKuwaiti Minister says OPEC unlikely to cut production, WSJ says
Subscribe for More Information
13:45 EDTXOMSaudis take aggressive oil measures in Europe, WSJ says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use